These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 12742294)

  • 1. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.
    Shekelle PG; Rich MW; Morton SC; Atkinson CS; Tu W; Maglione M; Rhodes S; Barrett M; Fonarow GC; Greenberg B; Heidenreich PA; Knabel T; Konstam MA; Steimle A; Warner Stevenson L
    J Am Coll Cardiol; 2003 May; 41(9):1529-38. PubMed ID: 12742294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.
    Vantrimpont P; Rouleau JL; Wun CC; Ciampi A; Klein M; Sussex B; Arnold JM; Moyé L; Pfeffer M
    J Am Coll Cardiol; 1997 Feb; 29(2):229-36. PubMed ID: 9014971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction.
    Exner DV; Dries DL; Waclawiw MA; Shelton B; Domanski MJ
    J Am Coll Cardiol; 1999 Mar; 33(4):916-23. PubMed ID: 10091816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE inhibitors in heart failure: what more do we need to know?
    Demers C; Mody A; Teo KK; McKelvie RS
    Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked suppression of renin levels by beta-receptor blocker in patients treated with standard heart failure therapy: a potential mechanism of benefit from beta-blockade.
    Holmer SR; Hengstenberg C; Mayer B; Engel S; Löwel H; Riegger GA; Schunkert H
    J Intern Med; 2001 Feb; 249(2):167-72. PubMed ID: 11240846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of race in the pharmacotherapy of heart failure.
    Kalus JS; Nappi JM
    Ann Pharmacother; 2002 Mar; 36(3):471-8. PubMed ID: 11895062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive beneficial effects of beta blockers in the prevention of symptomatic heart failure.
    Genovesi Ebert A; Colivicchi F; Malvezzi Caracciolo M; Riccio C
    Monaldi Arch Chest Dis; 2009 Mar; 72(1):18-22. PubMed ID: 19645208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction.
    Shlipak MG; Browner WS; Noguchi H; Massie B; Frances CD; McClellan M
    Am J Med; 2001 Apr; 110(6):425-33. PubMed ID: 11331052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of increased dose of diuretics on symptoms, weight, 6-minute walk distance, and echocardiographic measurements of left ventricular systolic and diastolic function in 51 patients with symptomatic heart failure caused by reduced left ventricular ejection fraction treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Kumar A; Aronow WS; Vadnerkar A; Sivan K; Mittal S
    Am J Ther; 2009; 16(1):5-7. PubMed ID: 19142162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
    Aronow WS
    J Lab Clin Med; 2001 May; 137(5):316-23. PubMed ID: 11329528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients.
    Roy P; Bouchard J; Amyot R; Madore F
    Am J Kidney Dis; 2006 Oct; 48(4):645-51. PubMed ID: 16997061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
    Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
    Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
    Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and pharmacological treatment of left-ventricular dysfunction in patients undergoing vascular surgery.
    Flu WJ; van Kuijk JP; Galal W; Kuiper R; van de Ven LL; Verhagen HJ; Bax JJ; Poldermans D
    Eur J Heart Fail; 2010 Mar; 12(3):288-93. PubMed ID: 20097682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure.
    Thornton PL; Ahmed A
    J Am Coll Cardiol; 2004 Apr; 43(7):1333; author reply 1333-4. PubMed ID: 15063454
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacotherapy for systolic dysfunction: a review of randomized clinical trials.
    Gheorghiade M; Benatar D; Konstam MA; Stoukides CA; Bonow RO
    Am J Cardiol; 1997 Oct; 80(8B):14H-27H. PubMed ID: 9372994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. beta-Blocker therapy in heart failure.
    Doughty RN
    Heart Fail Monit; 2000; 1(1):2-7. PubMed ID: 12634875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of > 35,000 patients.
    Peck KY; Lim YZ; Hopper I; Krum H
    Int J Cardiol; 2014 May; 173(2):197-203. PubMed ID: 24636548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.